#Germany #Berlin #Biotheryx #BTX-9341 #ESMO 2026

Biotheryx's Groundbreaking Presentation at ESMO 2026

Biotheryx, a prominent biopharmaceutical firm, is set to unveil its significant insights on BTX-9341, a cutting-edge CDK4/6 degrader tailored for the treatment of HR+/HER2- breast cancer.

This revelation comes within the context of the 2026 European Society for Medical Oncology (ESMO) Breast Cancer Annual Congress, scheduled from May 6 to May 8, 2026, in Berlin, Germany. The session promises to spotlight advancements and new therapeutic avenues in the fight against this formidable cancer.

Key Details of the Study

The focus of the presentation will be the Phase 1A Dose Escalation Study, which assesses BTX-9341 in combination with fulvestrant for HR+/HER2- breast cancer patients who have progressed following previous CDK4/6 inhibitor therapy. This duo aims to offer enhanced treatment options in cases where conventional therapies falter.

Presentation Highlights:

• - Title of the Study: Dose optimization of BTX-9341, a pioneering CDK4/6 bifunctional degrader, in patients previously treated with CDK4/6 inhibitors.
• - Presenter: Dr. Matthew Goetz from Mayo Clinic will deliver this informative session.
• - Session Details: It will take place on May 8, 2026, during the Rapid Oral Session 2 at Berlin Hall, from 8:30 to 10:00 AM.

About BTX-9341

BTX-9341 distinguishes itself as an innovative oral degrader, specifically targeting CDK4/6 proteins, which are vital for various cancers, including HR+/HER2- breast cancer. Preclinical studies suggest that BTX-9341 surpasses existing CDK4/6 inhibitors, thanks to its potent and selective mechanism that catalyzes the degradation of both CDK4 and CDK6.

Additionally, this innovative drug exhibits strong inhibition of CDK2 and Cyclin E transcription, leading to effective cell cycle arrest and improved efficacy in preclinical breast cancer models. One standout feature of BTX-9341 is its potential to overcome significant resistance mechanisms that challenge the current CDK4/6 inhibitors' impact in HR+/HER2- metastatic breast cancer settings.

What Sets Biotheryx Apart

The company prides itself on developing a robust portfolio of first-in-class protein degraders—systems designed to address significant gaps in therapy. Their PRODEGY platform, reflecting the expertise of its pioneering scientific team, is aimed at targeting proteins that have been deemed undruggable through traditional methods.

Biotheryx's pipeline not only includes BTX-9341, currently in the early stages of clinical evaluation, but also other promising bifunctional degraders addressing various cancer types. This commitment to innovation underpins their reputation as leaders in the biopharmaceutical landscape.

Conclusion

With ESMO 2026 presenting a global stage for cutting-edge oncology research, Biotheryx's upcoming presentation adds a vital chapter to the evolving narrative of targeted cancer therapies. By showcasing BTX-9341’s potential to significantly enhance treatment for patients who've exhausted conventional options, the company stands at the forefront of transformative cancer therapeutics. For more in-depth information on their advancements, visit Biotheryx's official website and engage with them on LinkedIn.

• ---